{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-301873","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2022-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.652617+00:00","generated_at":"2026-06-21T06:49:48.277380+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ARS Pharmaceuticals appoints Brian Dorsey as COO; salary increased to $410,000","bullets":["Brian Dorsey appointed COO effective December 6, 2022; previously SVP of Operations and Project Management since 2018.","Base salary raised from $319,800 to $410,000; eligible for annual discretionary bonus up to 40% of base salary.","Employment agreement is part-time (~35%); Dorsey may engage in other business activities, subject to non-compete in nasal drug development.","Severance: 3 months base salary and COBRA premiums if terminated without cause or resigns for good reason after 12-month cliff.","Dorsey holds 120,000-share option grant under 2018 Equity Incentive Plan, vesting monthly over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-301873","json":"https://secwatch.observer/filing/0001193125-22-301873.json","markdown":"https://secwatch.observer/filing/0001193125-22-301873.md","text":"https://secwatch.observer/filing/0001193125-22-301873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522301873/0001193125-22-301873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522301873/d772949d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:49:48.277380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7760c57a8a","claim":"Brian T. Dorsey was appointed as Chief Operations Officer at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Effective as of December 6, 2022, ARS Pharmaceuticals, Inc. (the “Company”) appointed Brian T. Dorsey, MSc, as Chief Operations Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522301873/0001193125-22-301873-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operations Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}